4-iodo-1-methyl-1H-indazol-3-amine | 796967-84-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 4-iodo-1-methyl-1H-indazol-3-amine
• 英文别名: 4-iodo-1-methylindazol-3-amine
• CAS: 796967-84-5
• 化学式: C₈H₈IN₃
• 分子量: 273.076
• InChiKey: DYHNOSXMWMDZRC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-iodo-1-methyl-1H-indazol-3-amine 在 palladium bis[bis(diphenylphosphino)ferrocene] dichloride 、 三乙胺 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 生成 3-Amino-1-methyl-1H-indazole-4-carboxylic acid
  参考文献：
  名称：

  Exploration of diverse hinge-binding scaffolds for selective Aurora kinase inhibitors

  摘要：

  Four hinge-binding scaffolds have been explored for novel selective Aurora kinase inhibitors. The structure activity relationship, selectivity and pharmacokinetic profiles have been evaluated. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.05.125
• 作为产物：
  描述：

  2-氟-6-碘苯甲腈 、 甲基肼 以 N,N-二甲基乙酰胺 为溶剂， 反应 21.0h， 以81%的产率得到4-iodo-1-methyl-1H-indazol-3-amine
  参考文献：
  名称：

  Structure−Activity Relationship Studies Leading to the Identification of (2E)-3-[l-[(2,4-Dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a Potent and Selective Prostanoid EP3 Receptor Antagonist, as a Novel Antiplatelet Agent That Does Not Prolong Bleeding

  摘要：

  The EP(3) receptor on the platelet mediates prostaglandin E(2) potentiation of thrombogenic coagonists including collagen and adenosine diphosphate (ADP). A pharmacophore driven approach led to the identification of diverse peri-substituted heterocycles as potent and selective EP(3) receptor antagonists. A simultaneous chemical optimization and druglike assessment of prioritized molecules converged oil a lead compound 50 (DG-041) that displayed favorable in vitro and functional activities as an inhibitor of human platelet aggregation. This agent is currently in human clinical trials for the treatment of atherothrombosis.

  DOI：

  10.1021/jm9005912

文献信息

• Sulfonamide peri-substituted bicyclics for occlusive artery disease
  申请人：Singh Jasbir

  公开号：US20060079520A1

  公开（公告）日：2006-04-13

  Acyl sulfonamide, peri-substituted, fused bicyclic ring compounds useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed. The compounds are of the general formula A representative example is:

  酰基磺酰胺，带有周取代的融合双环环化合物，用于治疗或预防前列腺素介导的疾病或症状。这些化合物的一般公式为 代表性示例是：
• Indazole and benzisoxazole kinase inhibitors
  申请人：——

  公开号：US20040235892A1

  公开（公告）日：2004-11-25

  Compounds having the formula 1 are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有以下化学式的化合物对抑制蛋白酪氨酸激酶具有用处。本发明还公开了制备这些化合物的方法、含有这些化合物的组合物，以及使用这些化合物进行治疗的方法。
• [EN] INDAZOLES, BENZISOXAZOLES AND BENZISOTHIAZOLES AS INHIBITORS OF PROTEIN KINASES<br/>[FR] INDAZOLES, BENZISOXAZOLES ET BENZISOTHIAZOLES EN TANT QU'INHIBITEURS DES PROTÉINES KINASES
  申请人：ABBOTT LAB

  公开号：WO2009012312A1

  公开（公告）日：2009-01-22

  Compounds that inhibit Aurora-kinases, compositions containing the compounds and methods of treating diseases using the compounds are disclosed.

  揭示了抑制极化激酶的化合物、含有这些化合物的组合物以及利用这些化合物治疗疾病的方法。
• NOVEL INDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING CANCER CONTAINING THE SAME
  申请人：KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

  公开号：US20200392127A1

  公开（公告）日：2020-12-17

  Disclosed are a compound selected from novel indazole derivatives, pharmaceutically acceptable salts thereof, hydrates thereof and stereoisomers thereof, a method for preparing the compound, and a pharmaceutical composition for preventing, alleviating or treating cancer containing the compound as an active ingredient. The novel indazole derivatives exhibit excellent ABL/DDR1 inhibitory efficacy and anti-proliferative efficacy against cancer cells, specifically blood cancer cells, and inhibitory activity against ABL T315I point mutations, thus being useful for the prevention, alleviation or treatment of cancer, specifically blood cancer, especially chronic myelogenous leukemia.

  揭示了一种选择自新型吲唑衍生物、其药学上可接受的盐、水合物和立体异构体的化合物，以及一种制备该化合物的方法和一种含有该化合物作为活性成分的用于预防、缓解或治疗癌症的药物组合物。新型吲唑衍生物展现出优秀的ABL/DDR1抑制效力和抗癌细胞增殖效力，特别针对血癌细胞，以及对ABL T315I点突变的抑制活性，因此对于预防、缓解或治疗癌症，特别是血癌，尤其是慢性髓系白血病具有用处。
• [EN] INDAZOLE, BENZISOXAZOLE, AND BENZISOTHIAZOLE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE KINASES DE TYPE INDAZOLE, BENZISOXAZOLE ET BENZISOTHIAZOLE
  申请人：ABBOTT LAB

  公开号：WO2004113304A1

  公开（公告）日：2004-12-29

  Compounds having the formula (I) are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

  具有（I）式的化合物对于抑制蛋白酪氨酸激酶是有用的。本发明还公开了制备该化合物的方法、含有该化合物的组合物以及使用该化合物的治疗方法。